Recurrent Implantation Failure: Immune Factors Testing and ERA Endometrial Receptivity Guide
Recurrent Implantation Failure: Immune Factors Testing and ERA Endometrial Receptivity Guide Key Takeaways: Recurrent Implantation Failure (RIF) — defined as three or more failed transfers of high-qu...
Recurrent Implantation Failure: Immune Factors Testing and ERA Endometrial Receptivity Guide
Key Takeaways: Recurrent Implantation Failure (RIF) — defined as three or more failed transfers of high-quality embryos — affects approximately 10–15% of IVF patients. AddBaby Medical & Fertility Center investigates five root-cause categories systematically, combining ERA endometrial receptivity testing with comprehensive immune screening to uncover the true reason for failure and deliver a personalized treatment strategy that significantly improves subsequent success rates.
Quick Reference Summary
| Item | Details |
|---|---|
| Who This Applies To | Patients with 2+ high-quality embryo transfer failures |
| ERA Test Cost | Approx. CNY 10,000–20,000 |
| Immune Screening Cost | Approx. CNY 5,000–15,000 |
| ERA Testing Timeline | 4–6 weeks including one full menstrual cycle |
| Success Rate Improvement | 20–40% improvement in implantation rates after targeted intervention |
| AddBaby's Approach | Multidisciplinary team (MDT) consultation with individualized precision protocols |
What Is Recurrent Implantation Failure (RIF)?
In IVF treatment, a failed transfer is a painful but common experience. However, when good-quality embryos are transferred repeatedly and none implant, something more systematic is at work. This is what reproductive medicine calls Recurrent Implantation Failure (RIF).
The most widely used clinical definition of RIF is: three or more failed transfers of good-quality embryos (including at least two top-grade blastocysts) without achieving clinical pregnancy. Some centers apply a more proactive threshold of two failures to initiate a deeper workup.
The Scale of RIF
Globally, approximately 10–15% of IVF patients experience RIF. Behind this statistic are countless couples caught in a cycle of hope and disappointment. What makes RIF particularly distressing is the "unexplained" diagnosis many patients receive — "your embryos look fine, your uterus looks fine, we don't know why it's not working." That uncertainty is often harder to bear than the failure itself.
AddBaby Medical & Fertility Center's multidisciplinary investigation protocol was built specifically to break that cycle. In the vast majority of RIF cases, a systematic workup reveals one or more addressable contributors — and targeted intervention can make the critical difference.
The Five Root Causes of Recurrent Implantation Failure
RIF originates from either the embryo or the maternal environment. AddBaby categorizes the causes into five groups:
Category 1: Embryo Factors (Chromosomal Abnormalities)
This is the most common — and most frequently underestimated — cause of RIF. Even morphologically perfect-looking embryos can harbor chromosomal aneuploidy (incorrect chromosome number). The prevalence rises steeply with maternal age:
- Under 35 years: approximately 40–50% of embryos have chromosomal abnormalities
- 38–40 years: approximately 60–70% of embryos have chromosomal abnormalities
- Over 42 years: more than 80% of embryos may carry chromosomal issues
Solution: PGT-A (Preimplantation Genetic Testing for Aneuploidies) — blastocyst biopsy followed by Next-Generation Sequencing (NGS) to screen all 24 chromosomes. Transferring only euploid (chromosomally normal) embryos dramatically improves implantation rates. Learn more on our IVF-PGD services page.
Category 2: Endometrial Factors
Even when embryo quality is optimal, implantation cannot occur if the uterine lining cannot provide a receptive environment:
- Insufficient endometrial thickness: Lining below 7 mm at ovulation, poor subendometrial blood flow
- Uterine structural anomalies: Endometrial polyps (common and easily missed), intrauterine adhesions, uterine septum
- Submucosal fibroids: Fibroids protruding into the uterine cavity disrupt endometrial vascularity and receptivity
- Chronic endometritis: Subclinical inflammation caused by low-grade infection, often asymptomatic
Solution: Hysteroscopy (identify and remove polyps, lyse adhesions), endometrial scratching (stimulate local regeneration), antibiotic and anti-inflammatory protocols.
Category 3: Immune Factors
Immune dysregulation has emerged as one of the most clinically significant — and historically most undertested — causes of RIF. AddBaby treats this as a priority investigation area.
Elevated Natural Killer (NK) Cell Activity: Uterine NK cells normally orchestrate implantation by remodeling the endometrium and regulating trophoblast invasion. But when their activity is pathologically elevated, they can destroy the implanting embryo rather than assist it. Testing: peripheral blood NK cell proportion and cytotoxicity; endometrial NK cell density via biopsy.
Antiphospholipid Syndrome (APS): Autoantibodies target phospholipid-binding proteins, causing microvascular thrombosis in the developing placenta and cutting off embryonic blood supply. This is one of the leading identified immunological causes of both implantation failure and recurrent miscarriage. Testing: lupus anticoagulant, anticardiolipin antibodies (IgG/IgM), anti-beta-2-glycoprotein-I antibodies.
Thrombophilia (Clotting Disorders): Inherited or acquired coagulation abnormalities impair microcirculation within the endometrium:
- Factor V Leiden gene mutation
- Prothrombin gene (F2) mutation
- MTHFR gene variants (folate metabolism impairment, elevated homocysteine)
- Protein S or Protein C deficiency
- Antithrombin III (AT-III) deficiency
Th1/Th2 Immune Imbalance: An overly aggressive maternal immune response fails to develop the necessary tolerance toward the embryo (which carries paternal antigens). This requires normalization of regulatory T-cell (Treg) function.
Category 4: Timing Factors (Displaced Window of Implantation)
This is one of the most important discoveries in reproductive medicine in recent decades: the Window of Implantation (WOI) is not identical for every patient.
Standard frozen embryo transfer (FET) protocols assume that the endometrium becomes maximally receptive at P+5 (120 hours after starting progesterone supplementation). Research now shows that approximately 30% of RIF patients have a displaced WOI:
- Pre-receptive: The window opens 1–3 days earlier than the standard timepoint
- Post-receptive: The window opens 1–3 days later than the standard timepoint
- Receptive but misdiagnosed: The WOI timing is standard, but a different protocol issue was masking it
The implication is stark: even a chromosomally normal, morphologically perfect embryo cannot implant if it arrives at the endometrium outside its individualized receptivity window — like knocking on exactly the right door but at the wrong time.
Solution: ERA testing (detailed in the next section).
Category 5: Additional Contributing Factors
- High Sperm DNA Fragmentation: Fragmented sperm DNA impairs early embryo development after fertilization. Even morphologically normal sperm can carry significant DNA damage. Testing: TUNEL assay or SCSA; normal threshold is below 15% fragmentation.
- Hydrosalpinx: Fluid accumulating in blocked fallopian tubes can reflux into the uterine cavity, exerting a direct toxic effect on embryos and impairing endometrial receptivity. Management: laparoscopic ligation or salpingectomy before IVF.
- Metabolic Factors: Uncontrolled thyroid dysfunction (TSH above 2.5 mIU/L), hyperprolactinemia, or insulin resistance can impair endometrial receptivity and luteal phase support.
ERA Testing in Depth: Finding Your Personal Implantation Window
ERA (Endometrial Receptivity Array) is currently the most validated, commercially available tool for identifying a patient's individualized implantation window. It is performed routinely at leading reproductive centers worldwide and at AddBaby's Bangkok facility.
The Science Behind ERA
ERA analyzes gene expression in endometrial biopsy tissue, evaluating more than 238 genes whose expression patterns are specifically associated with endometrial receptivity status. The result classifies the endometrium at the moment of biopsy as one of three states:
- Pre-receptive: The endometrium has not yet entered its receptivity window; transfer was attempted too early
- Receptive: The endometrium is in its optimal implantation window; this is the ideal transfer timepoint
- Post-receptive: The endometrium has passed its optimal window; transfer was attempted too late
The ERA Testing Process — Step by Step
- Simulate Transfer Cycle: In the ERA testing month, the endometrium is prepared using the exact same protocol (estrogen + progesterone) that will be used in the actual transfer cycle
- Endometrial Biopsy: At the standard P+5 timepoint (120 hours after progesterone initiation), a small amount of endometrial tissue is collected using a thin biopsy catheter (procedure takes approximately 5 minutes; mild discomfort)
- Sample Analysis: Tissue is fixed and sent to the ERA laboratory for RNA extraction and gene expression microarray analysis
- Report Interpretation: Results are returned in approximately 7–14 days, identifying receptivity status and providing a recommended personalized Embryo Transfer (pET) time if the standard timing was incorrect
- Transfer at the Personalized Timepoint: In the following cycle, embryo transfer is scheduled precisely at the ERA-recommended timepoint
When ERA Is and Is Not Appropriate
ERA is recommended when:
- Two or more high-quality embryo transfers have failed
- There is a history of recurrent pregnancy loss
- Optimizing the very first transfer in a high-risk patient (e.g., advanced age, previous cycle concerns)
- Preparing for frozen embryo transfer (FET), particularly with a programmed protocol
ERA limitations to understand:
- ERA addresses only the timing dimension of implantation failure; it does not resolve embryo quality issues, immune problems, or structural uterine factors
- In a small subset of patients (~2–4%), the WOI may shift slightly between cycles; repeat testing may occasionally be needed
- The test requires one full additional menstrual cycle, adding 4–6 weeks to the treatment timeline
- Cost is approximately CNY 10,000–20,000 and is typically not covered by insurance
Clinical Evidence Supporting ERA
Multiple prospective studies show that for RIF patients, ERA-guided personalized embryo transfer timing delivers:
- Approximately 20–25% improvement in clinical pregnancy rates
- Approximately 18–22% improvement in live birth rates
- Approximately 15% reduction in miscarriage rates
Complete Immune Factor Screening Checklist
For RIF patients where immune causes are suspected, AddBaby recommends a systematic three-tier workup:
Tier 1: Baseline Autoimmune Panel
| Test | Purpose | Normal Reference |
|---|---|---|
| Anticardiolipin antibodies (ACA-IgG/IgM) | Antiphospholipid syndrome | Negative |
| Anti-beta-2-glycoprotein-I antibodies | Antiphospholipid syndrome | Negative |
| Lupus anticoagulant (LA) | Antiphospholipid syndrome | Negative |
| Antinuclear antibodies (ANA) | Systemic autoimmune disease | Negative / low titer |
| Thyroid antibodies (TPO-Ab / TG-Ab) | Autoimmune thyroid disease | Negative |
Tier 2: Complete Thrombophilia Panel
| Test | Purpose |
|---|---|
| Coagulation screen (PT / APTT / TT / Fibrinogen) | Baseline clotting function |
| D-dimer | Thrombosis risk assessment |
| Protein C activity | Inherited thrombophilia |
| Protein S activity | Inherited thrombophilia |
| Antithrombin III (AT-III) | Inherited thrombophilia |
| MTHFR gene variant testing | Folate metabolism / thrombosis risk |
| Factor V Leiden mutation | Inherited thrombosis |
Tier 3: NK Cell Function Testing (When Tier 1–2 Results Are Abnormal or RIF Remains Unexplained)
- Peripheral blood NK cell percentage and cytotoxicity (normal: NK cells comprising 12–18% of lymphocytes)
- Endometrial NK cell density via biopsy (provides a more direct measure of local uterine immune activity)
Personalized Treatment Based on Test Findings
Once the underlying cause is identified, AddBaby's multidisciplinary team designs a targeted intervention plan:
For Immune Factor Abnormalities
Antiphospholipid antibodies positive / Thrombophilia confirmed:
- Low Molecular Weight Heparin (LMWH): Started before transfer and continued through the first trimester
- Low-dose aspirin (75–100 mg/day): Improves endometrial perfusion
- High-dose folic acid and B-vitamin supplementation for patients with MTHFR variants
Elevated NK cell activity:
- Intravenous Immunoglobulin (IVIG): Modulates immune response and reduces NK cytotoxicity
- Low-dose corticosteroids (prednisolone 5–10 mg/day): Suppresses excessive immune activation
- Intralipid infusion: An emerging alternative to IVIG with comparable NK-suppressing data
For Displaced WOI (ERA Abnormal Result)
- Transfer time adjusted strictly according to ERA-recommended pET window
- Pre-receptive patients: transfer moved 24–48 hours earlier
- Post-receptive patients: transfer delayed by 24–72 hours
- Progesterone start time recalculated backward from the target pET timepoint
For Endometrial Factors
- Endometrial scratching: Performed in the cycle before transfer; triggers local cytokine release and endometrial renewal
- Hysteroscopic surgery: Polypectomy, adhesiolysis — clear structural obstacles first
- Platelet-Rich Plasma (PRP) intrauterine infusion: Promotes endometrial repair in thin-lining cases
- G-CSF (Granulocyte Colony-Stimulating Factor) intrauterine infusion: Improves endometrial receptivity, particularly in refractory thin endometrium
How AddBaby Handles Recurrent Implantation Failure
With 15 years of experience and over 5,000 cases treated, AddBaby Medical & Fertility Center handles more than 100 RIF referrals annually. Our protocol is built on four principles:
Step 1: Systematic Root-Cause Investigation
At the initial RIF consultation, our reproductive specialist reviews the patient's full history: every retrieval cycle's egg count and quality, all embryo grading records, details of each transfer protocol, uterine ultrasound findings, and results of any prior investigations. This comprehensive review identifies what has and has not been tested, and which gaps are most likely to contain the answer.
Step 2: Multidisciplinary Team Consultation
For complex RIF cases, AddBaby convenes a formal MDT meeting involving reproductive endocrinology, immunology, and genetics specialists. Each discipline evaluates the case from its own framework and contributes to a unified treatment recommendation — a process that frequently reveals connections that a single-specialty view would miss.
Step 3: Phased, Prioritized Intervention
Rather than layering every possible intervention simultaneously (which makes it impossible to identify what worked), AddBaby implements targeted interventions in a logical sequence, with clear evaluation points between stages.
Step 4: Continuous Monitoring and Protocol Adaptation
Every transfer cycle is preceded by a detailed case review and followed by thorough outcome analysis. The protocol is treated as a living document — adjusted based on new evidence as the cycle progresses. Contact us through the AddBaby patient inquiry page to schedule a complimentary RIF consultation.
Frequently Asked Questions
Q1: How accurate is ERA testing? Can the result be used for future cycles?
A: ERA's accuracy has been validated at approximately 89–95% across multiple multicenter clinical trials. The result reflects your endometrium's gene expression profile under a specific hormone protocol, and this profile tends to be stable across subsequent cycles when the same protocol is used. Most patients can rely on the same ERA result for 1–2 years without retesting. However, if the stimulation protocol changes significantly (e.g., switching from an oral to injectable estrogen regimen, or changing progesterone type or dose), a new ERA may be warranted since the WOI can shift with protocol modifications.
Q2: What are the risks and side effects of immune treatments like IVIG?
A: Intravenous immunoglobulin (IVIG) has a well-established safety profile in reproductive immunology, having been used in this context for over 30 years. Common mild side effects include transient headache, low-grade fever, or muscle aches during the infusion, typically resolving within 24 hours. Serious adverse events — anaphylaxis, renal impairment — are extremely rare (occurring in under 0.1% of infusions). Low-dose corticosteroids such as prednisolone 5–10 mg/day are equally well-tolerated, and their use in early pregnancy has a robust safety record. All immune interventions at AddBaby are carried out under physician supervision with regular monitoring of immune and organ function markers.
Q3: After multiple transfer failures, do I need to do a new egg retrieval cycle?
A: Not necessarily — and we avoid unnecessary retrieval whenever possible. If high-quality frozen embryos (especially PGT-A normal ones) remain in storage, the priority is investigating maternal causes — endometrial, immune, and timing factors — before recommending another retrieval. A new retrieval cycle should be considered only when: all existing frozen embryos have been transferred or are of poor quality, testing reveals embryo-side factors as the primary cause (particularly if PGT-A was never performed), or the patient's advancing age makes it advantageous to bank additional embryos now. AddBaby's principle is to maximize the utility of existing embryos before subjecting patients to additional retrieval procedures.
Conclusion
Recurrent implantation failure is not a verdict — it is a diagnostic signal demanding a more thorough investigation. Through ERA endometrial receptivity testing, comprehensive immune screening, and multidisciplinary case review, AddBaby Medical & Fertility Center has helped hundreds of RIF patients identify the true cause of their treatment failures and achieve pregnancy through personalized, evidence-based intervention.
If you have experienced two or more IVF transfer failures, the path forward is not to repeat the same approach and hope for a different outcome. It is to find out why it failed — and then fix it.
Contact us today through our patient consultation page to schedule a complimentary RIF specialist review. We also offer comprehensive IVF-PGD services with full PGT-A screening, and our IVF Success Guarantee Plan for patients seeking both clinical excellence and financial protection on the journey to parenthood.
This article has been reviewed by the reproductive endocrinology and immunology teams at AddBaby Medical & Fertility Center. Content is for informational purposes only and does not constitute medical advice. Individual clinical circumstances vary significantly; please consult a qualified specialist for personalized evaluation and treatment planning. Last updated: February 2026
